Revenue
2022
2023
2024
2025
Theracryf plc (TCF)
Price£0.00185Cached quote
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £0 | £396,000 | £442,000 | £0 |
| Research & development | £1.1M | £2.6M | £3.3M | £2.5M |
| Operating expenses | £2.1M | £4.0M | £5.5M | £3.2M |
| Operating income | −£2.1M | −£3.6M | −£5.1M | −£3.2M |
| Operating margin | — | −898.99% | −1,147.06% | — |
| EBITDA | −£2.0M | −£3.5M | −£5.1M | −£3.2M |
| EBITDA margin | — | −895.96% | −1,144.12% | — |
| Net income | −£1.9M | −£3.1M | −£4.0M | −£2.7M |
| Net profit margin | — | −792.17% | −914.71% | — |
| Basic EPSper basic share | -£0.00 | -£0.01 | -£0.01 | -£0.01 |
| Diluted EPSper diluted share | -£0.00 | -£0.01 | -£0.01 | -£0.01 |
Community posts
TheraCryf approves £1.05m capital raise and share-capital reorganisation
TheraCryf confirmed on 7 September 2026 that shareholders approved its approximately £1.05m gross capital raise and the related subdivision of share capital. Shares and dates The placing and subscription will issue 583,333,328 new ordinary ...